BRPI0413452A - composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv - Google Patents

composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv

Info

Publication number
BRPI0413452A
BRPI0413452A BRPI0413452-4A BRPI0413452A BRPI0413452A BR PI0413452 A BRPI0413452 A BR PI0413452A BR PI0413452 A BRPI0413452 A BR PI0413452A BR PI0413452 A BRPI0413452 A BR PI0413452A
Authority
BR
Brazil
Prior art keywords
methods
cancer
kit
therapeutic
compound
Prior art date
Application number
BRPI0413452-4A
Other languages
English (en)
Inventor
Jun Feng
Stephen L Gwaltney
Stephen W Kaldor
Jeffrey A Stafford
Michael B Wallace
Zhiyuan Zhang
Bruce Elder
Paul Isbester
Grant Palmer
Luckner Ulysse
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BRPI0413452A publication Critical patent/BRPI0413452A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, KIT, ARTIGO DE FABRICAçãO, E, MéTODOS DE INIBIR DPP-IV, TERAPêUTICO E DE TRATAR UM ESTADO DE DOENçA, CáNCER DISTúRBIOS AUTOIMUNES, UMA CONDIçãO E INFECçãO POR HIV". Os compostos, os produtos farmacêuticos, kits e métodos são fornecidos para o uso com inibidores de DPP-IV que compreendem a Fórmula (I), em que os substituintes são como descritos neste.
BRPI0413452-4A 2003-08-13 2004-08-12 composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv BRPI0413452A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49523803P 2003-08-13 2003-08-13
PCT/US2004/026265 WO2005016911A1 (en) 2003-08-13 2004-08-12 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0413452A true BRPI0413452A (pt) 2006-10-17

Family

ID=33564066

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413452-4A BRPI0413452A (pt) 2003-08-13 2004-08-12 composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv

Country Status (17)

Country Link
US (6) US7790736B2 (pt)
EP (1) EP1506967B1 (pt)
JP (1) JP4854943B2 (pt)
KR (1) KR20060041309A (pt)
CN (1) CN1867560A (pt)
AR (1) AR045455A1 (pt)
AU (1) AU2004265341A1 (pt)
BR (1) BRPI0413452A (pt)
CA (1) CA2535619A1 (pt)
DE (1) DE602004010206T2 (pt)
IL (1) IL173490A0 (pt)
MX (1) MXPA06001601A (pt)
NO (1) NO20061157L (pt)
RU (1) RU2006107553A (pt)
TW (1) TW200524895A (pt)
WO (1) WO2005016911A1 (pt)
ZA (1) ZA200602051B (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8025566B2 (en) * 2003-04-16 2011-09-27 Igt Gaming device methods and apparatus employing audio/video programming outcome presentation
CN1723196A (zh) 2001-06-27 2006-01-18 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
EP1699777B1 (en) * 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
UA85871C2 (uk) * 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
CN1956974B (zh) * 2004-05-19 2010-11-24 巴斯福股份公司 2-取代嘧啶及其作为农药的用途
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
MX2007013430A (es) 2005-04-29 2008-03-19 Univ California Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
JP5075125B2 (ja) 2005-08-26 2012-11-14 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防用ジペプチジルペプチダーゼｉｖ阻害剤としての縮合アミノピペリジン
PT1931350E (pt) 2005-09-14 2014-02-12 Takeda Pharmaceutical Administração de inibidores de dipeptidil peptidase
MY147393A (en) * 2005-09-14 2012-11-30 Takeda Pharmaceutical Administration of dipeptidyl peptidase inhibitors
PE20070622A1 (es) * 2005-09-14 2007-08-22 Takeda Pharmaceutical Administracion de inhibidores de dipeptidil peptidasa
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
CA2622642C (en) * 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
JP5094416B2 (ja) * 2005-12-28 2012-12-12 武田薬品工業株式会社 糖尿病治療剤
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007112368A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
AU2007235876A1 (en) 2006-04-12 2007-10-18 Probiodrug Ag Enzyme inhibitors
KR20090031605A (ko) * 2006-07-04 2009-03-26 아스트라제네카 아베 신규한 피리딘 유사체
TW200811133A (en) * 2006-07-04 2008-03-01 Astrazeneca Ab New pyridine analogues III 334
AU2007284801A1 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
MX2009002772A (es) * 2006-09-13 2009-05-28 Takeda Pharmaceutical Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro- 2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo.
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
EA020870B1 (ru) 2007-07-19 2015-02-27 Такеда Фармасьютикал Компани Лимитед Твердый препарат, включающий алоглиптин и гидрохлорид метформина
UY32126A (es) * 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
US20100144140A1 (en) * 2008-12-10 2010-06-10 Novellus Systems, Inc. Methods for depositing tungsten films having low resistivity for gapfill applications
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
CN102791701B (zh) 2009-12-30 2014-02-12 深圳信立泰药业股份有限公司 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US20130303551A1 (en) * 2011-01-10 2013-11-14 Nicholas D. Adams Pyrimidinone derivatives as fatty acid synthase inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US20140213502A1 (en) 2011-04-29 2014-07-31 United States Department of Health and Human Services Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
CN103044392B (zh) * 2011-10-13 2015-10-14 连云港润众制药有限公司 一种高效的dpp-iv抑制剂的制备方法
CN103044391B (zh) * 2011-10-13 2015-11-25 中国科学院广州生物医药与健康研究院 一种高效的dpp-iv抑制剂
US9732085B2 (en) 2011-12-21 2017-08-15 Ono Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor Xia
BR112014030284B1 (pt) 2012-07-18 2021-11-30 Sunshine Lake Pharma Co., Ltd Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
US9902712B2 (en) 2013-12-19 2018-02-27 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
BR112017012146B1 (pt) 2014-12-10 2023-11-21 Ono Pharmaceutical Co., Ltd Composto derivado de di-hidroindolizinona, seu uso, composição farmacêutica e inibidor de fxia
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
CN107250126B (zh) * 2015-11-05 2019-10-25 四川科伦博泰生物医药股份有限公司 长效二肽基肽酶-iv抑制剂、其用途及其制备方法
CA3026149A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
SI3571193T1 (sl) 2017-01-23 2022-04-29 Cadent Therapeutics, Inc. Modulatorji kalijevega kanalčka
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
WO2019241574A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood sugar with a dipeptidyl peptidase-4 inhibitor pharmaceutical composition
CA3116339A1 (en) 2018-10-22 2020-04-30 Cadent Therapeutics, Inc. Crystalline forms of potassium channel modulators

Family Cites Families (417)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB699812A (en) * 1950-11-29 1953-11-18 British Ind Solvents Ltd Manufacture of substituted pyrimidones
GB1053063A (pt) * 1963-05-18
DE1670912C3 (de) 1967-08-18 1981-06-11 Bayer Ag, 5090 Leverkusen Herbizide Mittel auf Basis von 1,2,4-Triazin-5-onen
GB1377642A (en) 1971-01-14 1974-12-18 Koninklijke Gist Spiritus Penicillanic and cephalosporanic acid derivatives
US3960949A (en) * 1971-04-02 1976-06-01 Schering Aktiengesellschaft 1,2-Biguanides
DE2150686A1 (de) 1971-10-12 1973-04-19 Basf Ag 6-amino-uracil-5-carbonsaeurethioamide
BE792206A (pt) * 1971-12-02 1973-06-01 Byk Gulden Lomberg Chem Fab
AU5996573A (en) 1972-09-11 1975-03-06 Commonwealth Scientific And Industrial Research Organisation Pyridinium salts
US3823135A (en) 1972-12-26 1974-07-09 Shell Oil Co Pyrimidone herbicides
GB1464248A (en) 1973-11-01 1977-02-09 Ici Ltd Substituted triazinediones their preparation and use as herbicides
DE2361551A1 (de) 1973-12-11 1975-06-19 Basf Ag Wasserloesliche azofarbstoffe
DE2500024A1 (de) 1975-01-02 1976-07-08 Basf Ag Wasserloesliche azofarbstoffe
JPS535180A (en) 1976-07-01 1978-01-18 Sumitomo Chem Co Ltd Preparation of 3,4-dihydro-2 (1h) quinazoline derivatives
DE2720085A1 (de) 1977-05-05 1978-11-16 Hoechst Ag Pyrimido(6,1-a)isochinolin-2-on- derivate
US4494978A (en) 1976-12-30 1985-01-22 Chevron Research Company Herbicidal N-(N'-hydrocarbyloxycarbamylalkyl)-2,6-dialkyl-alpha-haloacetanilides
CH657851A5 (de) 1983-06-28 1986-09-30 Ciba Geigy Ag Chromogene chinazolonverbindungen.
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
EP0260621A3 (de) * 1986-09-18 1989-03-15 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft 3-Aryluracil-enoläther und deren Verwendung zur Unkrautbekämpfung
EP0842925A1 (en) 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
WO1989010701A1 (fr) 1988-05-05 1989-11-16 Basf Aktiengesellschaft Produits a base de derives d'uracil pour stimuler la croissance et reduire la graisse chez les animaux
GB8900382D0 (en) 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
IE63502B1 (en) 1989-04-21 1995-05-03 Zeneca Ltd Aminopyrimidine derivatives useful for treating cardiovascular disorders
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
JPH05504969A (ja) 1990-02-13 1993-07-29 メルク・エンド・カムパニー・インコーポレーテツド 置換ベンジル要素を含有するアンギオテンシン２アンタゴニスト類
US5814460A (en) 1990-02-14 1998-09-29 Diatide, Inc. Method for generating and screening useful peptides
US5366862A (en) 1990-02-14 1994-11-22 Receptor Laboratories, Inc. Method for generating and screening useful peptides
US5462928A (en) 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
DE4110019C2 (de) 1991-03-27 2000-04-13 Merck Patent Gmbh Imidazopyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US5387512A (en) 1991-06-07 1995-02-07 Merck & Co. Inc. Preparation of 3-[z-benzoxazol-2-yl)ethyl]-5-(1-hydroxyethyl)-6-methyl-2-(1H)-pyridinone by biotransformation
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
CA2121369C (en) 1991-10-22 2003-04-29 William W. Bachovchin Inhibitors of dipeptidyl-aminopeptidase type iv
US5350752A (en) 1991-12-16 1994-09-27 E. R. Squibb & Sons, Inc. Dihydropyrimidine derivatives
DE4141788A1 (de) 1991-12-18 1993-06-24 Merck Patent Gmbh Imidazopyridine
TW229142B (pt) 1992-04-15 1994-09-01 Nissan Detrochem Corp
DE4305602A1 (de) 1992-06-17 1993-12-23 Merck Patent Gmbh Imidazopyridine
WO1994003055A1 (en) 1992-07-31 1994-02-17 The Government Of The United States Of America, Asrepresented By The Secretary Of The Department Of Health And Human Services Producing increased numbers of hematopoietic cells by administering inhibitors of dipeptidyl peptidase iv
NZ248573A (en) 1992-09-10 1996-02-27 Lilly Co Eli 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions
IL106998A0 (en) * 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
US5811281A (en) 1993-07-12 1998-09-22 Cornell Research Foundation, Inc. Immortalized intestinal epithelial cell lines
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
DE4341453A1 (de) 1993-12-06 1995-06-08 Merck Patent Gmbh Imidazopyridine
EP0749974B1 (en) 1994-03-08 2001-06-27 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivative
US5580979A (en) 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US5543396A (en) 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
AU2790895A (en) 1994-06-10 1996-01-05 Universitaire Instelling Antwerpen Purification of serine protease and synthetic inhibitors thereof
CA2194014C (en) 1994-06-17 2009-10-06 Trobe University (La) Biological control of insects
US5601986A (en) 1994-07-14 1997-02-11 Amgen Inc. Assays and devices for the detection of extrahepatic biliary atresia
DE4432860A1 (de) 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE69526969T2 (de) * 1994-12-14 2003-03-20 Du Pont-Mitsui Polychemicals Co., Ltd. Thermoplastische harzzusammensetzung und seine verwendung
KR100275300B1 (ko) 1995-04-13 2000-12-15 고바야시 유키오 신규 4,6-디아릴피리미딘 유도체 및 그 염(novel 4,6-diarylpyrimidine derivatives and salts thereof)
US5614379A (en) * 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
US6325989B1 (en) 1995-06-01 2001-12-04 Dana-Farber Cancer Institute, Inc. Form of dipeptidylpeptidase IV (CD26) found in human serum
US6265551B1 (en) 1995-06-01 2001-07-24 Dana-Farber Cancer Institute, Inc. Form of dipeptidylpeptidase IV (CD26) found in human serum, antibodies thereto, and uses thereof
ATE201016T1 (de) 1995-06-09 2001-05-15 Hoffmann La Roche Pyrimidindion-, pyrimidintrion-, triazindion- derivate als alpha-1-adrenergische rezeptorantagonisten
JPH0928376A (ja) 1995-07-21 1997-02-04 Ajinomoto Co Inc 新規ジペプチジルペプチダーゼｉｖとその製造方法
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
US20020006899A1 (en) 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US5965532A (en) 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
CA2258949C (en) 1996-07-01 2008-05-06 Reddy-Cheminor, Inc. Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1998018763A1 (en) 1996-10-25 1998-05-07 Tanabe Seiyaku Co., Ltd. Tetrahydroisoquinoline derivatives
US6011155A (en) 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
EP0948496A2 (en) * 1996-12-05 1999-10-13 Amgen inc. Substituted pyrimidinone and pyridone compounds and methods of use
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US20030060434A1 (en) 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US6100234A (en) 1997-05-07 2000-08-08 Tufts University Treatment of HIV
ATE414775T1 (de) 1997-05-16 2008-12-15 Novozymes Inc Polypeptide mit prolyldipeptidylaminopeptidase- aktivität und dafür kodierende nukleinsäuren
EP0897012A1 (en) 1997-07-05 1999-02-17 Societe Des Produits Nestle S.A. Cloning of the prolyl-dipeptidyl-peptidase from aspergillus oryzae
US6235493B1 (en) * 1997-08-06 2001-05-22 The Regents Of The University Of California Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
ATE357509T1 (de) 1997-09-29 2007-04-15 Point Therapeutics Inc Stimulierung von hämatopoietischen zellen im vitro
WO1999017799A1 (en) 1997-10-06 1999-04-15 Trustees Of Tufts College Et Al. Cytoplasmic dipeptidylpeptidase iv from human t-cells
US6485955B1 (en) 1997-10-06 2002-11-26 The Trustees Of Tufts University Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease
US6342611B1 (en) * 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
EA200000408A1 (ru) 1997-10-10 2000-12-25 Сайтовиэ, Инк. Новые флуоресцентные сигнальные молекулы и их применение, в том числе, в анализах каспаз
DE69839279T2 (de) 1997-11-18 2009-05-28 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Neue physiologisch aktive substanz sulphostin, herstellung und verwendung derselben
FR2771004B1 (fr) * 1997-11-19 2000-02-18 Inst Curie Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
WO1999028474A2 (en) 1997-12-01 1999-06-10 The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services Chemokine variants and methods of use
AU755387B2 (en) 1997-12-16 2002-12-12 Japan Tobacco Inc. Polypeptides having aminopeptidase activity and nucleic acids encoding same
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
EP2583675A1 (en) 1998-02-02 2013-04-24 Trustees Of Tufts College Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
JP2002506075A (ja) 1998-03-09 2002-02-26 フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ セリンペプチダーゼ調節剤
US20020061839A1 (en) * 1998-03-09 2002-05-23 Scharpe Simon Lodewijk Serine peptidase modulators
WO1999047152A2 (en) 1998-03-20 1999-09-23 Sloan Kettering Institute For Cancer Research Use of dipeptidyl peptidase (dpp4) of fibroblast activating protein alpha for suppressing the malignant phenotype of cancer cells
JP2003504301A (ja) 1998-04-01 2003-02-04 ブリストル−マイヤーズ スクイブ ファーマ カンパニー インテグリンアンタゴニスト
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
JP2002517401A (ja) * 1998-06-05 2002-06-18 ポイント セラピューティクス， インコーポレイテッド 環状ボロプロリン化合物
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US6129911A (en) 1998-07-10 2000-10-10 Rhode Island Hospital, A Lifespan Partner Liver stem cell
ATE251465T1 (de) 1998-07-31 2003-10-15 Novo Nordisk As In-vitro stimulation von beta zellen vermehrung
DE19834591A1 (de) * 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Verfahren zur Steigerung des Blutglukosespiegels in Säugern
DE69941510D1 (de) 1998-08-10 2009-11-19 Us Gov Nat Inst Health Differenzierung von nicht-insulin in insulin-produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
WO2000010549A1 (en) 1998-08-21 2000-03-02 Point Therapeutics, Inc. Regulation of substrate activity
EP1113804A2 (en) 1998-09-17 2001-07-11 Akesis Pharmaceuticals, Inc. Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
DE19845153A1 (de) 1998-10-01 2000-04-06 Merck Patent Gmbh Imidazo[4,5]-pyridin-4-on-derivate
US20030176357A1 (en) 1998-10-06 2003-09-18 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
DE19900471A1 (de) 1999-01-08 2000-07-13 Merck Patent Gmbh Imidazo[4,5c]-pyridin-4-on-derivate
ATE356117T1 (de) 1999-01-22 2007-03-15 Kirin Brewery Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität
US7396809B1 (en) 1999-02-10 2008-07-08 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
WO2000053171A1 (en) 1999-03-05 2000-09-14 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
GB9906714D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for improving fertility
GB9906715D0 (en) * 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
WO2000057721A2 (en) 1999-03-26 2000-10-05 Akesis Pharmaceuticals, Inc. Edible solids for treatment of glucose metabolism disorders
US6548529B1 (en) * 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
EP1171438A1 (en) 1999-04-20 2002-01-16 Novo Nordisk A/S Compounds, their preparation and use
BR0010750A (pt) 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
DE19926233C1 (de) 1999-06-10 2000-10-19 Probiodrug Ges Fuer Arzneim Verfahren zur Herstellung von Thiazolidin
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6172081B1 (en) 1999-06-24 2001-01-09 Novartis Ag Tetrahydroisoquinoline 3-carboxamide derivatives
US6107317A (en) 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6617340B1 (en) 1999-07-29 2003-09-09 Novartis Ag N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
DE19940130A1 (de) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
JP4748908B2 (ja) 1999-09-10 2011-08-17 ザ・ユニバーシティ・オブ・シドニー ジペプチジルペプチダーゼ
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
EP1216233A1 (en) 1999-09-28 2002-06-26 MERCK PATENT GmbH Quinazolinones
US6447772B1 (en) 1999-10-01 2002-09-10 Klaire Laboratories, Inc. Compositions and methods relating to reduction of symptoms of autism
US6251391B1 (en) * 1999-10-01 2001-06-26 Klaire Laboratories, Inc. Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons
CA2392209A1 (en) 1999-10-08 2001-04-19 Kazuyuki Fujishima M-substituted benzoic acid derivatives having integrin .alpha.v.beta.3 antagonistic activity
US6261794B1 (en) 1999-10-14 2001-07-17 Saint Louis University Methods for identifying inhibitors of methionine aminopeptidases
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US20040152745A1 (en) 1999-11-12 2004-08-05 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
JP2003535034A (ja) 1999-11-12 2003-11-25 ギルフォード ファーマシューティカルズ インコーポレイテッド ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
AU2020501A (en) 1999-12-08 2001-06-18 1149336 Ontario Inc. Chemotherapy treatment
US6380398B2 (en) 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1743655B1 (en) 2000-01-21 2014-06-25 Novartis AG Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
WO2001055105A1 (en) 2000-01-24 2001-08-02 Novo Nordisk A/S N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
WO2001055119A2 (en) 2000-01-25 2001-08-02 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
MXPA02007231A (es) 2000-01-27 2002-12-09 Lilly Co Eli Proceso para solubilizar los compuestos de peptido 1 similares a glucagon.
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
EP1259246A2 (en) 2000-02-25 2002-11-27 Novo Nordisk A/S Use of dpp-iv inhibitors for the treatment of diabetes
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6448045B1 (en) 2000-03-10 2002-09-10 The Regents Of The University Of California Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1
US6608038B2 (en) 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
EP1136482A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
KR20080067009A (ko) * 2000-03-31 2008-07-17 프로시디온 리미티드 디펩티딜 펩티다제 ⅳ 효소 활성 억제제를 포함하는약제학적 조성물
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US7022702B2 (en) 2000-04-07 2006-04-04 Qlt Inc. Antiproliferative 1,2,3-thiadiazole compounds
US6545170B2 (en) * 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
EP1288216A1 (en) 2000-04-18 2003-03-05 Sumitomo Pharmaceuticals Company, Limited Tricyclic quinazolinediones
GEP20084317B (en) * 2000-04-25 2008-02-25 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0010188D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
DE10025464A1 (de) 2000-05-23 2001-12-06 Inst Medizintechnologie Magdeb Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen
US6783757B2 (en) 2000-06-01 2004-08-31 Kirkman Group, Inc. Composition and method for increasing exorphin catabolism to treat autism
AU2001263786A1 (en) 2000-06-09 2001-12-17 Prozymex A/S Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
US6432969B1 (en) 2000-06-13 2002-08-13 Novartis Ag N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
AU2001268958B2 (en) * 2000-07-04 2006-03-09 Novo Nordisk A/S Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
WO2002004610A2 (en) 2000-07-10 2002-01-17 Bayer Aktiengesellschaft Regulation of human dipeptidyl-peptidase iv-like enzyme
TW535080B (en) 2000-07-24 2003-06-01 Ten Square Co Ltd Method and apparatus for optimal fitting activities into customer idle time
JP2002042960A (ja) * 2000-07-25 2002-02-08 Yazaki Corp コネクタ支持機構
MXPA03000772A (es) 2000-08-01 2003-06-04 Pharmacia Corp Derivados de acido hexahidro-7-1h-azepin-2-il-hexanoico como inhibidores de oxido nitrico sintasa inducible.
US7022711B2 (en) 2000-08-04 2006-04-04 Warner-Lambert Company 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimidin-7-ones
JP4101053B2 (ja) 2000-08-10 2008-06-11 田辺三菱製薬株式会社 プロリン誘導体及びその医薬用途
US20020165237A1 (en) 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
US20020037829A1 (en) * 2000-08-23 2002-03-28 Aronson Peter S. Use of DPPIV inhibitors as diuretic and anti-hypertensive agents
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
CA2422057C (en) 2000-09-08 2012-11-27 Prozymex A/S Dipeptidyl peptidase i crystal structure and its uses
US20020064736A1 (en) 2000-09-27 2002-05-30 Fuji Photo Film Co., Ltd. Dye-forming coupler, silver halide photographic light-sensitive material, and method for producing an azomethine dye
JP2004513090A (ja) * 2000-09-27 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病及び脂質異常症の治療のためのベンゾピランカルボン酸誘導体
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
SE0003599D0 (sv) 2000-10-05 2000-10-05 Thomas Johansson Anordning för fuktabsorption
BR0114436A (pt) * 2000-10-06 2003-07-01 Tanabe Seiyaku Co Composto com anel de cinco elementos contendo nitrogênio alifático
PL366005A1 (en) 2000-10-12 2005-01-24 Ferring Bv Novel serine protease genes related to dppiv
AUPR107800A0 (en) * 2000-10-27 2000-11-23 University Of Sydney, The Peptide and nucleic acid molecule ii
CA2424475A1 (en) 2000-10-27 2002-05-02 Probiodrug Ag Method for the treatment of neurological and neuropsychological disorders
PT1333887E (pt) * 2000-10-30 2006-10-31 Ortho Mcneil Pharm Inc Metodo de tratamento de desordens musculares
US6586198B2 (en) 2000-10-31 2003-07-01 Vanderbilt University Method of identifying susceptibility to angiotensin converting enzyme inhibto- and vasopeptidase-inhibitor-associated angioedema
AU2002248221B2 (en) 2000-10-31 2006-08-17 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
AU2002225954A1 (en) 2000-11-08 2002-05-21 The University Of Georgia Research Foundation, Inc. Dipeptidylpeptidases and methods of use
TWI243162B (en) * 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
US20030055052A1 (en) * 2000-11-10 2003-03-20 Stefan Peters FAP-activated anti-tumor compounds
US20020155565A1 (en) 2000-11-10 2002-10-24 Pilar Garin-Chesa FAP-activated anti-tumor compounds
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
EP1343763A1 (en) * 2000-11-20 2003-09-17 Bristol-Myers Squibb Company Pyrodone derivatives as ap2 inhibitors
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
CA2433090A1 (en) 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
CA2627862C (en) 2001-01-02 2009-12-22 Imtm Gmbh Use of inhibitors of dipeptidyl peptidase iv (dp iv) in combination with inhibitors of alanyl-aminopeptidase (apn)
DE10100053A1 (de) 2001-01-02 2002-08-22 Keyneurotek Ag I G Verwendung von Enzyminhibitoren der Dipeptidylpeptidase IV sowie der Aminopeptidase N und pharmazeutischen Zubereitungen daraus zur Prävention und/oder Therapie Ischämie-bedingter akuter und chronischer neurodegenerativer Prozesse und Erkrankungen
WO2002059301A1 (en) 2001-01-27 2002-08-01 K.U. Leuven Research And Development Chemokines
SK10802003A3 (sk) 2001-02-02 2004-05-04 Takeda Chemical Industries, Ltd. Kondenzovaná heterocyklická zlúčenina, jej použitie a jej farmaceutický prípravok
TWI255817B (en) 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
WO2002066627A1 (en) 2001-02-16 2002-08-29 Bayer Aktiengesellschaft Regulation of human dipeptidyl peptidase 8
EP1368349B1 (de) * 2001-02-24 2007-02-14 Boehringer Ingelheim Pharma GmbH & Co.KG Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
US6337069B1 (en) 2001-02-28 2002-01-08 B.M.R.A. Corporation B.V. Method of treating rhinitis or sinusitis by intranasally administering a peptidase
JP4178816B2 (ja) 2001-03-15 2008-11-12 田辺三菱製薬株式会社 医薬組成物
AU2002251067B2 (en) * 2001-03-19 2005-05-26 Novartis Ag Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
EP1385508B1 (en) 2001-03-27 2008-05-21 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
FR2822826B1 (fr) * 2001-03-28 2003-05-09 Servier Lab Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE10115921A1 (de) 2001-03-30 2002-10-02 Boehringer Ingelheim Pharma Verfahren zur Herstellung von 4,6-Diaminopyrimido[5,4-d]pyrimidinen
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
US7812148B2 (en) 2001-04-05 2010-10-12 Millipore Corporation Vectors comprising CpG islands without position effect varigation and having increased expression
GB0109146D0 (en) 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
PE20021080A1 (es) 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
EP1389194A2 (en) * 2001-04-27 2004-02-18 Vertex Pharmaceuticals Incorporated Inhibitors of bace
KR100863624B1 (ko) 2001-05-11 2008-10-15 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Ｃｄ26을 발현하는 세포와 연관된 질환의 치료제로사용되는 항-ｃｄ26 단클론항체
FR2824825B1 (fr) 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030060494A1 (en) 2001-05-18 2003-03-27 Nobuyuki Yasuda Pharmaceutical use of N-carbamoylazole derivatives
US7105556B2 (en) 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
US6794379B2 (en) * 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
CA2450579A1 (en) 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
ES2257555T3 (es) 2001-06-20 2006-08-01 MERCK & CO., INC. Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes.
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
ATE380175T1 (de) 2001-06-27 2007-12-15 Smithkline Beecham Corp Pyrrolidine als dipeptidyl peptidase inhibitoren
CN1723196A (zh) 2001-06-27 2006-01-18 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
JP4357293B2 (ja) 2001-06-27 2009-11-04 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
DE10150203A1 (de) 2001-10-12 2003-04-17 Probiodrug Ag Peptidylketone als Inhibitoren der DPIV
RU2003105463A (ru) 2001-06-27 2004-11-27 Пробиодруг Аг (De) Пептидные структуры, пригодные для конкурентного модулирования катализа, осуществляемого дипептидилпептидазой iv
EP1399470A2 (en) 2001-06-27 2004-03-24 Probiodrug AG Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
US20030135023A1 (en) 2001-06-27 2003-07-17 Hans-Ulrich Demuth Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis
DE60225556D1 (de) 2001-07-03 2008-04-24 Novo Nordisk As Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
US6869947B2 (en) 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
WO2003007888A2 (en) 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
AU2002330672A1 (en) 2001-07-25 2003-02-17 Genset S.A. Gmg-1 polynucleotides and polypeptides and uses thereof
EP1436392A2 (en) 2001-07-26 2004-07-14 Genset S.A. Gmg-2 polynucleotides and polypeptides and uses thereof
JP2005503377A (ja) 2001-07-30 2005-02-03 ノボ　ノルディスク　アクティーゼルスカブ 新規ビニルｎ−（２−ベンゾイルフェニル）−ｌ−チロシン誘導体及び抗糖尿病剤等へのそれらの使用
RU2004105956A (ru) 2001-07-30 2005-03-27 Ново Нордиск А/С (DK) Новые производные винилкарбоновых кислот и их применение в качестве антидиабетических средств и т.п.
EP1414785A1 (en) 2001-07-30 2004-05-06 Novo Nordisk A/S Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
ATE408414T1 (de) 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
EP1572885A2 (en) 2001-08-08 2005-09-14 Genzyme Corporation Methods for treating diabetes and other blood sugar disorders
EP1285922A1 (en) 2001-08-13 2003-02-26 Warner-Lambert Company 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
WO2003016335A2 (en) 2001-08-13 2003-02-27 Probiodrug Ag Irreversible cysteine protease inhibitors of legumain
JP2003128551A (ja) 2001-08-15 2003-05-08 Sankyo Co Ltd 新規抗糖尿病医薬組成物
DE10143840A1 (de) 2001-09-06 2003-03-27 Probiodrug Ag Neue Inhibitoren der Dipeptidylpeptidase I
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
KR20040033048A (ko) 2001-09-14 2004-04-17 미츠비시 웰파마 가부시키가이샤 티아졸리딘 유도체 및 이의 약학적 용도
US6673829B2 (en) * 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
AU2002331311A1 (en) 2001-09-19 2003-04-01 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
IL160700A0 (en) 2001-09-21 2004-08-31 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
IL160701A0 (en) 2001-09-21 2004-08-31 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
CN104744461A (zh) 2001-09-21 2015-07-01 百时美施贵宝公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
HRP20040311A2 (en) 2001-10-01 2005-02-28 Bristol-Myers Squibb Company Cerep SA Spiro-hydantoin compounds useful as anti-inflammatory agents
WO2003030946A1 (en) 2001-10-09 2003-04-17 Novartis Ag Regulation of insulin production
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
GB0125446D0 (en) 2001-10-23 2001-12-12 Ferring Bv Novel anti-diabetic agents
GB0125445D0 (en) * 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
JP2005507261A (ja) 2001-10-31 2005-03-17 ノバルティス アクチエンゲゼルシャフト Ｔｃｆ１遺伝子における多型に基づく糖尿病および関連状態の治療方法
EP1442028A4 (en) 2001-11-06 2009-11-04 Bristol Myers Squibb Co SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS
US20030125304A1 (en) 2001-11-09 2003-07-03 Hans-Ulrich Demuth Substituted amino ketone compounds
US20030089935A1 (en) * 2001-11-13 2003-05-15 Macronix International Co., Ltd. Non-volatile semiconductor memory device with multi-layer gate insulating structure
WO2003045228A2 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
KR20040058307A (ko) 2001-11-26 2004-07-03 쉐링 코포레이션 비만 및 ｃｎｓ 장애를 치료하기 위한 피페리딘계 ｍｃｈ길항제
EP2316470A3 (en) 2001-11-26 2011-08-24 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
EP1458374A2 (en) 2001-12-14 2004-09-22 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
GB0129988D0 (en) 2001-12-14 2002-02-06 Ferring Bv Imidazolidineacetic acid derivatives
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
US7189888B2 (en) 2001-12-21 2007-03-13 Kimberly-Clark Worldwide, Inc. Nonabsorbent surge layer having discrete regions of superabsorbent and method for making
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
PL370989A1 (en) 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
AU2002360732A1 (en) 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
ES2280596T3 (es) 2001-12-29 2007-09-16 Novo Nordisk A/S Uso combinado de un compuesto de glp-1 y un inhibidor de una aldosa reductasa.
AU2003201274A1 (en) 2002-01-11 2003-07-24 Novo Nordisk A/S Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
US7101898B2 (en) 2002-02-01 2006-09-05 Novo Nordisk A/S Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
WO2003063903A2 (en) 2002-02-01 2003-08-07 Probiodrug Ag Modulation of t lymphocytes using dp iv inhibitors
AU2003207717B9 (en) 2002-02-01 2009-05-07 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
ES2252656T3 (es) 2002-02-13 2006-05-16 F. Hoffmann-La Roche Ag Nuevos derivados de piridina y quinolina.
JP4359146B2 (ja) 2002-02-13 2009-11-04 エフ．ホフマン−ラ ロシュ アーゲー 新規なピリジン−およびピリミジン−誘導体
CN1642599A (zh) 2002-02-27 2005-07-20 辉瑞产品公司 Acc抑制剂
CA2479812A1 (en) 2002-02-28 2003-09-04 Prosidion Ltd. Glutaminyl based dpiv inhibitors
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
ATE507210T1 (de) 2002-03-07 2011-05-15 X Ceptor Therapeutics Inc Chinazolinon modulatoren von nukleinrezeptoren
CA2478599A1 (en) 2002-03-11 2003-09-18 Novartis Ag Salts of nateglinide
MXPA04008901A (es) 2002-03-13 2004-11-26 Euro Celtique Sa Pirimidinas arilo sustituidas y el uso de las mismas.
DE10211555A1 (de) 2002-03-15 2003-10-02 Imtm Inst Fuer Medizintechnolo Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention dermatologischer Erkrankungen mit sebozytärer Hyperproliferation und veränderten Differenzierungszuständen
TW200810743A (en) 2002-03-22 2008-03-01 Novartis Ag Combination of organic compounds
CA2478389A1 (en) 2002-03-25 2003-10-09 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7348318B2 (en) 2002-03-25 2008-03-25 Nippon Kayaku Kabushiki Kaisha α-Amino-N-(diaminophosphinyl)lactam derivatives
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
US20040106802A1 (en) 2002-04-08 2004-06-03 Torrent Pharmaceuticals Ltd. Novel compounds and therapeutic uses thereof
WO2003084940A1 (en) 2002-04-08 2003-10-16 Alangudi Sankaranarayanan Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
JP2003300977A (ja) 2002-04-10 2003-10-21 Sumitomo Pharmaceut Co Ltd キサンチン誘導体
US7691967B2 (en) 2002-04-30 2010-04-06 Trustees Of Tufts College Smart pro-drugs of serine protease inhibitors
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
PT1551834E (pt) 2002-05-23 2010-09-30 Novartis Vaccines & Diagnostic Compostos de quinazolinona substituídos
US6818662B2 (en) 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
GB0212412D0 (en) 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
WO2003101449A2 (en) 2002-06-04 2003-12-11 Pfizer Products Inc. Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
JP2005533771A (ja) 2002-06-04 2005-11-10 ファイザー・プロダクツ・インク ジペプチジルペプチダーゼｉｖ阻害剤としてのフッ素化環式アミド
US6710040B1 (en) 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
AU2003241960B2 (en) 2002-06-06 2009-07-30 Eisai R&D Management Co., Ltd. Novel fused imidazole derivative
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
HUP0202001A2 (hu) 2002-06-14 2005-08-29 Sanofi-Aventis DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
US20040009972A1 (en) * 2002-06-17 2004-01-15 Ding Charles Z. Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
CA2489648A1 (en) 2002-06-17 2003-12-24 Smithkline Beecham Corporation Chemical process
SE0201976D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
US20040006004A1 (en) 2002-06-27 2004-01-08 Markku Koulu Method for prevention and treatment of diseases or disorders related to excessive formation of vascular tissue or blood vessels
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US20040054171A1 (en) 2002-07-04 2004-03-18 Jensen Anette Frost Polymorphic forms of a 4H-thieno[3,2-E]-1,2,4-thiadiazine 1,1-dioxide derivative
AU2003259131A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
WO2004004661A2 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
BR0312503A (pt) 2002-07-09 2007-06-26 Bristol Myers Squibb Co derivados heterocìclicos substituìdos úteis como agentes antidiabéticos e antiobesidade, composição farmacêutica, uso e combinação dos mesmos
AU2003248259A1 (en) 2002-07-10 2004-02-02 Yamanouchi Pharmaceutical Co., Ltd. Novel azetidine derivative or salt thereof
US7208498B2 (en) 2002-07-15 2007-04-24 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
JP2004099600A (ja) 2002-07-19 2004-04-02 Sankyo Co Ltd 二環性アミノ基置換化合物を含有する医薬組成物
AU2003253369A1 (en) 2002-07-29 2004-02-16 Tanabe Seiyaku Co., Ltd. Three-dimensional structure of dipeptidyl peptidase iv
TW200404060A (en) 2002-08-08 2004-03-16 Takeda Chemical Industries Ltd Fused heterocyclic compounds
ES2306781T3 (es) 2002-08-09 2008-11-16 Prosidion Ltd. Inhibidores de la dipeptidil-peptidasa iv para disminucion de la tasa de aumento cronico de peso.
ES2339112T3 (es) 2002-08-21 2010-05-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG 8-(3-amino-piperidin-1-il)-xantinas,su preparacion y su uso como medicamentos.
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
DE10238470A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10238477A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
KR100582141B1 (ko) 2002-08-29 2006-05-22 다이쇼 세이야꾸 가부시끼가이샤 4-플루오로-2-시아노피롤리딘 유도체 벤젠술폰산염
US6998502B1 (en) 2002-09-05 2006-02-14 Sabinsa Corporation Convenient process of manufacture for difluoromethylornithine and related compounds
EP1398032A1 (en) 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-Oxo-quinazolines as LXR nuclear receptor binding compounds
JP2004123738A (ja) 2002-09-11 2004-04-22 Takeda Chem Ind Ltd 徐放性製剤
AU2003262059A1 (en) 2002-09-11 2004-04-30 Takeda Pharmaceutical Company Limited Sustained release preparation
ATE461212T1 (de) 2002-09-18 2010-04-15 Prosidion Ltd Sekundäre bindungsstelle von dipeptidylpeptidase iv (dp iv)
US20040058876A1 (en) * 2002-09-18 2004-03-25 Torsten Hoffmann Secondary binding site of dipeptidyl peptidase IV (DP IV)
US7262207B2 (en) 2002-09-19 2007-08-28 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
CA2768674A1 (en) 2002-09-19 2004-04-01 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
MXPA05003252A (es) 2002-09-26 2005-07-05 Eisai Co Ltd Farmaco de combinacion.
US6869966B2 (en) 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives
ATE370141T1 (de) 2002-10-07 2007-09-15 Merck & Co Inc Antidiabetische heterocyclische beta- aminoverbindungen als inhibitoren von dipeptidylpeptidase
AU2003269850A1 (en) 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
WO2004032861A2 (en) 2002-10-11 2004-04-22 Bristol-Myers Squibb Company Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
CA2502269C (en) 2002-10-18 2009-12-22 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004037176A2 (en) 2002-10-21 2004-05-06 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
ATE469645T1 (de) 2002-10-23 2010-06-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
WO2004041795A1 (en) 2002-10-30 2004-05-21 Guilford Pharmaceuticals Inc. Novel inhibitors of dipeptidyl peptidase iv
CA2504735C (en) 2002-11-07 2009-06-23 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
EP1565437A1 (en) * 2002-11-18 2005-08-24 Pfizer Products Inc. Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
AU2002952946A0 (en) 2002-11-27 2002-12-12 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
UY28103A1 (es) 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
US7109192B2 (en) 2002-12-03 2006-09-19 Boehringer Ingelheim Pharma Gmbh & Co Kg Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
WO2004050022A2 (en) 2002-12-04 2004-06-17 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CN100376573C (zh) 2002-12-04 2008-03-26 卫材R&D管理有限公司 稠合的1,3-二氢-咪唑环化合物
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
CA2508947A1 (en) 2002-12-20 2004-07-15 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004062613A2 (en) 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
EP1589969A4 (en) 2003-01-17 2008-08-13 Merck & Co Inc 3-AMINO-4-PHENYLBUTANEAN DERIVATEALS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
JP4184378B2 (ja) 2003-01-31 2008-11-19 株式会社三和化学研究所 ジペプチジルペプチダーゼｉｖを阻害する化合物
CA2513684A1 (en) 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004071454A2 (en) 2003-02-13 2004-08-26 Guilford Pharmaceuticals Inc. Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308356A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2004076433A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
EP1626981A4 (en) 2003-03-04 2006-11-22 Biorexis Pharmaceutical Corp PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
AR043443A1 (es) 2003-03-07 2005-07-27 Merck & Co Inc Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios
US20050014732A1 (en) 2003-03-14 2005-01-20 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-diabetic agent
AR043505A1 (es) 2003-03-18 2005-08-03 Merck & Co Inc Preparacion de beta-cetoamidas e intermediarios de reaccion
WO2004085661A2 (en) 2003-03-24 2004-10-07 Merck & Co., Inc Process to chiral beta-amino acid derivatives
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
WO2004087880A2 (en) 2003-03-26 2004-10-14 Bayer Pharmaceuticals Corporation Compounds and their use to treat diabetes and related disorders
WO2004087650A2 (en) 2003-03-27 2004-10-14 Merck & Co. Inc. Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
WO2004089362A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S 2-cyanopyrroles and their analogues as ddp-iv inhibitors
JPWO2004096806A1 (ja) 2003-04-30 2006-07-13 大日本住友製薬株式会社 縮合イミダゾール誘導体
EP1961416B1 (en) * 2003-05-05 2013-01-23 Probiodrug AG Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis.
EP1622870A2 (en) 2003-05-05 2006-02-08 Prosidion Ltd. Glutaminyl based dp iv-inhibitors
CN1784220B (zh) 2003-05-05 2011-08-03 前体生物药物股份公司 谷氨酰胺酰基和谷氨酸环化酶效应物的应用
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
AU2003902260A0 (en) 2003-05-09 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
US7560455B2 (en) 2003-05-14 2009-07-14 Merck & Co., Inc. 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
WO2004101514A1 (ja) 2003-05-15 2004-11-25 Taisho Pharmaceutical Co., Ltd. シアノフルオロピロリジン誘導体
CN1798556A (zh) 2003-06-06 2006-07-05 麦克公司 作为治疗或者预防糖尿病的二肽基肽酶抑制剂的稠合吲哚
AU2003902946A0 (en) 2003-06-12 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
CN1809544A (zh) 2003-06-17 2006-07-26 麦克公司 作为二肽基肽酶抑制剂用于治疗或预防糖尿病的环己基甘氨酸衍生物
DE10327439A1 (de) 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) * 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
WO2005000848A1 (en) 2003-06-20 2005-01-06 F. Hoffmann-La Roche Ag Pyrido` 2, 1-a - isoquinoline derivatives as dpp-iv inhibitors
ATE437876T1 (de) 2003-06-20 2009-08-15 Hoffmann La Roche Hexahydropyridoisochinoline als dpp-iv- inhibitoren
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
AU2004254629B2 (en) 2003-07-01 2010-04-01 Jeld-Wen, Inc Methods and systems for the automated manufacture of composite doors
US7259160B2 (en) 2003-07-31 2007-08-21 Merck & Co., Inc. Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
WO2005019168A2 (en) 2003-08-20 2005-03-03 Pfizer Products Inc. Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
EP1699777B1 (en) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1697342A2 (en) 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
UA85871C2 (uk) 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
MY147393A (en) 2005-09-14 2012-11-30 Takeda Pharmaceutical Administration of dipeptidyl peptidase inhibitors
PE20070622A1 (es) 2005-09-14 2007-08-22 Takeda Pharmaceutical Administracion de inhibidores de dipeptidil peptidasa
PT1931350E (pt) * 2005-09-14 2014-02-12 Takeda Pharmaceutical Administração de inibidores de dipeptidil peptidase
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor

Also Published As

Publication number Publication date
US20050070535A1 (en) 2005-03-31
US20050070531A1 (en) 2005-03-31
CA2535619A1 (en) 2005-02-24
US7790736B2 (en) 2010-09-07
US7470700B2 (en) 2008-12-30
US20050070706A1 (en) 2005-03-31
EP1506967A1 (en) 2005-02-16
EP1506967B1 (en) 2007-11-21
MXPA06001601A (es) 2006-08-25
US7579357B2 (en) 2009-08-25
US20050070530A1 (en) 2005-03-31
US7723344B2 (en) 2010-05-25
IL173490A0 (en) 2006-06-11
KR20060041309A (ko) 2006-05-11
JP2005060401A (ja) 2005-03-10
DE602004010206T2 (de) 2008-10-09
TW200524895A (en) 2005-08-01
ZA200602051B (en) 2007-10-31
JP4854943B2 (ja) 2012-01-18
AR045455A1 (es) 2005-10-26
DE602004010206D1 (de) 2008-01-03
CN1867560A (zh) 2006-11-22
NO20061157L (no) 2006-05-11
RU2006107553A (ru) 2007-09-20
AU2004265341A1 (en) 2005-02-24
US20050065148A1 (en) 2005-03-24
WO2005016911A1 (en) 2005-02-24
US20050075330A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
ECSP055899A (es) Pirimidinas inhibidoras de chk, pdk y akt, su producción y su uso como agentes farmacéuticos
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos.
BRPI0416692A (pt) inibidores heterocìclicos de mek e métodos de emprego destes
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
BR0312957A (pt) Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
PA8432901A1 (es) Compuestos de piridilpirrol
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR0308212A (pt) Composto, composição farmacêutica, e, uso de um composto
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
BR0312464A (pt) Inibidores de tirosina quinases
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
BRPI0514371A (pt) 2, 4 di (aminofenil) pirimidina como inibidores de plk
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
BRPI0410760A (pt) compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
BRPI0514841A (pt) inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores
ATE408601T1 (de) Fredericamycin-derivate
UY28150A1 (es) Agentes terapeuticos
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
BRPI0412999A (pt) 2-aminotetralina substituìda para tratamento de depressão
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.